QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Teprotumumab, Thyroid Eye Disease and Product Pharmacovigilance

Test your understanding of the concepts covered by Teprotumumab: IGF-1 receptor biology, thyroid eye disease, and product pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the most defensible interpretation of teprotumumab’s mechanism in TED based on the article?

The complete molecular mechanism is established and proves that IGF-1R autoantibodies cause all TED The treatment directly cures the underlying Graves-related autoimmune tendency IGF-1R inhibition can reduce disease-relevant orbital outputs, but the precise human mechanism and role of IGF-1R-directed antibodies remain incompletely characterized Clinical efficacy cannot be accepted because the mechanism is not fully characterized

Question 2 of 10 What conclusion is best supported by evidence in patients with long-duration, low-activity TED?

Only actively inflamed disease can respond to IGF-1R inhibition A modifiable component may remain after obvious inflammation subsides, although fixed fibrosis and residual anatomy may persist All chronic diplopia and lid abnormalities should resolve without surgery The chronic-disease study proves that retreatment is routinely required

Question 3 of 10 Which counselling and risk-management statement best reflects the embryo-fetal concern associated with teprotumumab?

Pregnancy precautions are unnecessary because monoclonal antibodies cannot affect development Pregnancy should be managed according to current local product information, with pregnancy exclusion or testing as applicable and effective contraception during treatment and for six months afterward Contraception is required only until the first infusion is completed The concern is limited to male fertility and does not involve fetal development

Question 4 of 10 Which treatment-selection principle is most consistent with the article’s comparison of therapeutic approaches?

The same treatment should be used regardless of whether inflammation, proptosis, diplopia, or sight threat dominates Treatment choice should consider the dominant clinical problem, disease activity and severity, comorbidities, risks, availability, and local guidance Teprotumumab should replace urgent decompression whenever optic neuropathy is present Corticosteroids are expected to provide the same anatomical effect on proptosis as IGF-1R inhibition

Question 5 of 10 Which administration and observation practice is most consistent with the article’s safety framework?

Give one fixed dose to all patients and discharge immediately after infusion Use a 10 mg/kg loading dose followed by 20 mg/kg every three weeks for seven further infusions, with observation during infusion and for 90 minutes afterward Give 20 mg/kg daily until proptosis resolves Administer the treatment subcutaneously once monthly without infusion monitoring

Question 6 of 10 Which statement best reflects the relationship between TSHR and IGF-1R in thyroid eye disease?

Teprotumumab treats TED by binding and removing TSHR autoantibodies TSHR is irrelevant to TED once IGF-1R is expressed in orbital fibroblasts IGF-1R may function as a cooperating signalling hub, allowing TSHR-related signals to influence orbital fibroblast responses TSHR and IGF-1R are the same receptor expressed under different names

Question 7 of 10 Why is safety in retreated patients considered missing information in the European risk-management framework?

Retreatment was prohibited in all clinical studies The available retreatment groups were too small to define a dependable safety and retreatment strategy Retreatment has been proven universally unsafe The initial eight-infusion course prevents any possibility of later exposure

Question 8 of 10 Which description best characterizes teprotumumab’s primary pharmacological action?

It is an agonist that activates IGF-1R to restore orbital tissue homeostasis It is a receptor antagonist that reduces ligand-driven IGF-1R signalling and promotes receptor removal from the cell surface It is a depleting antibody that eliminates IGF-1R-expressing orbital fibroblasts It is a direct inhibitor of the intracellular insulin receptor kinase

Question 9 of 10 Which approach provides the strongest causality assessment for a new audiometric threshold shift after teprotumumab?

Assume causality solely because the event occurred after treatment Exclude causality because the patient had a history of noise exposure Integrate timing, objective audiometry, dechallenge or follow-up, alternative causes, concomitant ototoxic medicines, and any rechallenge information Rely only on whether the patient reported tinnitus

Question 10 of 10 Which case detail would most directly improve evaluation of suspected teprotumumab-associated hyperglycaemia?

Only the patient’s final eye colour Baseline HbA1c and glucose, serial values, diabetes treatment, steroid exposure, symptoms, ketones when indicated, and treatment changes The patient’s preferred infusion-room location A single glucose value with no timing or baseline information

Knowledge Assessment: Teprotumumab, Thyroid Eye Disease and Product Pharmacovigilance

Cookie Settings